2.3.2.3 Factor Xa inhibitors

Direct Oral Anticoagulants (DOACs) are recommended as first line treatment over Vitamin K antagonists (Warfarin) for treatment in newly initiated patients with non-valvular atrial fibrillation (NVAF) as per NICE NG196. Apixaban or Rivaroxaban (prescribed generically) is recommended as first line (preferred) DOAC in newly diagnosed patients with NVAF, unless contraindicated, not tolerated or clinically inappropriate.  Please see Kent and Medway ICB Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing, for advice on cost-effective choice of DOAC.

Please see Kent and Medway ICB Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing in nvAF

https://www.gov.uk/drug-safety-update/direct-acting-oral-anticoagulants-doacs-paediatric-formulations-reminder-of-dose-adjustments-in-patients-with-renal-impairment

Expand All / Expand All (incl. cost)

Prescribe Generically.

GP clincal info available on CCG website

Pack Price
10 tablet
20 tablet
60 tablet £2.91
Pack Price
28 tablet
56 tablet £2.83
60 tablet

Prescribe generically.

Prescribe after haematology recommendation only for the long term prevention of DVT or PE following treatment dose. Do not prescribe 10mg strength for patients with atrial fibrillation as 10mg strength not licensed for this use.

Pack Price
10 tablet
100 tablet
30 tablet £54.00
Pack Price
100 tablet
14 tablet
28 tablet £50.40
42 tablet
Pack Price
100 tablet
28 tablet £50.40
7 tablet
Pack Price
10 tablet £17.50
Pack Price
28 tablet £49.00
Pack Price
28 tablet £49.00
Pack Price
10 pre-filled disposable injection £62.79
7 pre-filled disposable injection
Pack Price
10 pre-filled disposable injection £62.79
Pack Price
10 pre-filled disposable injection £116.53
Pack Price
10 pre-filled disposable injection £116.53
Pack Price
10 pre-filled disposable injection £116.53